Oncology · Clinical trials
Cervical Cancer Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About cervical cancer — and why its trials are hard
Cervical cancer is predominantly caused by persistent high-risk human papillomavirus (HPV) infection and, despite effective screening and vaccination, remains a major cause of cancer death in under-resourced settings. Most tumors are squamous cell carcinomas or adenocarcinomas. Early-stage disease is curable with surgery or chemoradiation, but persistent, recurrent or metastatic disease has historically carried a poor prognosis. Trials are challenging for several reasons. In high-income countries incidence is falling, so accrual to advanced-disease trials is slow and often relies on international sites with variable radiotherapy quality. Prior pelvic radiation limits tolerance of subsequent systemic therapy and complicates response assessment in irradiated fields. PD-L1 expression (measured by combined positive score) and HPV biology modulate immunotherapy benefit, requiring biomarker stratification. Patients often have significant symptom burden, renal compromise from obstruction, and socioeconomic barriers to follow-up, all of which affect endpoint measurement and retention. Cytotoxic backbones plus bevacizumab set a meaningful efficacy bar for newer agents.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Bevacizumab (Avastin) | 2014 | Persistent/recurrent/metastatic, added to chemotherapy | GOG-240 | Overall survival | Median OS 16.8 vs 13.3 months (HR 0.77) |
| Pembrolizumab (Keytruda) | 2021 | First-line persistent/recurrent/metastatic, +chemo +/- bevacizumab (CPS >= 1) | KEYNOTE-826 | Overall survival | OS HR 0.64 (CPS >= 1); final median OS 28.6 vs 16.5 months in all-comers (HR 0.63) |
| Tisotumab vedotin (Tivdak) | 2021 (accelerated); 2024 (full) | Recurrent/metastatic after prior chemotherapy | innovaTV 301 | Overall survival | Median OS 11.5 vs 9.5 months (HR 0.70) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in cervical cancer development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Durvalumab — CALLA | Adding durvalumab to and after chemoradiation did not significantly improve progression-free survival in locally advanced cervical cancer | Concurrent chemoradiation may already induce strong local control; trial design and patient selection (unenriched for PD-L1) likely limited detectable benefit |
Choosing the right endpoint
Primary endpoints that matter in cervical cancer trials
- Overall survival (OS) — Primary endpoint in GOG-240, KEYNOTE-826 and innovaTV 301
- Progression-free survival (PFS) — Co-primary in immunotherapy combination trials; primary in chemoradiation studies like CALLA
- PD-L1 combined positive score (CPS) — Key predictive biomarker guiding pembrolizumab eligibility
- Objective response rate (ORR) — Basis for tisotumab vedotin's initial accelerated approval (innovaTV 204)
How iNGENū runs cervical cancer trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Cervical Cancer clinical trials — FAQs
How has immunotherapy changed advanced cervical cancer treatment?
What is tisotumab vedotin and who is it for?
Why is bevacizumab used in cervical cancer?
Ready to discuss your cervical cancer trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal